These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 36636438)

  • 21. Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer.
    Shao J; Wang C; Ren P; Jiang Y; Tian P; Li W
    Biosci Rep; 2020 May; 40(5):. PubMed ID: 32315071
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiotoxicity in cancer immune-checkpoint therapy: Mechanisms, clinical evidence, and management strategies.
    Sun JY; Qu Q; Lou YX; Hua Y; Sun GZ; Sun W; Kong XQ
    Int J Cardiol; 2021 Dec; 344():170-178. PubMed ID: 34563597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival.
    Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M
    World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Arrhythmic events associated with immune checkpoint inhibitors therapy: A real-world study based on the Food and Drug Administration Adverse Event Reporting System database.
    Liu Y; Chen Y; Zeng Z; Liu A
    Cancer Med; 2023 Mar; 12(6):6637-6648. PubMed ID: 36426382
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune-related adverse events in various organs caused by immune checkpoint inhibitors.
    Okiyama N; Tanaka R
    Allergol Int; 2022 Apr; 71(2):169-178. PubMed ID: 35101349
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
    Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
    Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States.
    Jain P; Gutierrez Bugarin J; Guha A; Jain C; Patil N; Shen T; Stanevich I; Nikore V; Margolin K; Ernstoff M; Velcheti V; Barnholtz-Sloan J; Dowlati A
    ESMO Open; 2021 Oct; 6(5):100252. PubMed ID: 34461483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune Checkpoint Therapies and Atherosclerosis: Mechanisms and Clinical Implications: JACC State-of-the-Art Review.
    Vuong JT; Stein-Merlob AF; Nayeri A; Sallam T; Neilan TG; Yang EH
    J Am Coll Cardiol; 2022 Feb; 79(6):577-593. PubMed ID: 35144750
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuro-ophthalmic Complications of Immune-Checkpoint Inhibitors.
    Mukharesh L; Chwalisz BK
    Semin Ophthalmol; 2021 May; 36(4):241-249. PubMed ID: 33641589
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune-checkpoint inhibitor resistance in cancer treatment: Current progress and future directions.
    Zhang C; Zhang C; Wang H
    Cancer Lett; 2023 May; 562():216182. PubMed ID: 37076040
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [IMMUNE CHECKPOINT INHIBITOR-INDUCED DIABETES MELLITUS].
    Fischer M; Amos S; Levy L; Pollack R
    Harefuah; 2021 Oct; 160(10):657-662. PubMed ID: 34689435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis.
    Mori K; Abufaraj M; Mostafaei H; Quhal F; Fajkovic H; Remzi M; Karakiewicz PI; Egawa S; Schmidinger M; Shariat SF; Gust KM
    Eur Urol; 2021 Jun; 79(6):783-792. PubMed ID: 33172722
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article.
    Chen CH; Yu HS; Yu S
    Curr Oncol; 2022 Apr; 29(4):2871-2886. PubMed ID: 35448208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer patients receiving immune checkpoint inhibitor therapy are at an increased risk for atherosclerotic cardiovascular disease.
    Lutgens E; Seijkens TTP
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32034065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
    Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Compartmentalization of Intrarenal Programmed Cell Death Protein 1-Ligand 1 and Its Receptor in Kidney Injury Related to Immune Checkpoint Inhibitor Nephrotoxicity.
    Tampe D; Kopp SB; Baier E; Hakroush S; Tampe B
    Front Med (Lausanne); 2022; 9():902256. PubMed ID: 35755033
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer.
    Xiong W; Zhao Y; Du H; Guo X
    Front Oncol; 2021; 11():704336. PubMed ID: 34490104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.